Community/Retail

The FDA has approved Novo Nordisk’s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The FDA has extended the approval of raltegravir (Isentress, Merck), an integrase inhibitor for use in combination with other antiretroviral agents, for the treatment of HIV-1 in newborn infants weighing at least 2 kg.